Online inquiry

IVTScrip™ mRNA-Anti-CXCL10, BMS-936557(Cap 0, Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ4511MR)

This product GTTS-WQ4511MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & Pseudo-UTP. It ecodes the monoclonal antibody that targets CXCL10 gene. The antibody can be applied in Rheumatoid arthritis (RA) research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_001565.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3627
UniProt ID P02778
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CXCL10, BMS-936557(Cap 0, Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ4511MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ3027MR IVTScrip™ mRNA-Anti-ITGA4&ITGB7&ITGAE, Anti-Beta7(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA Anti-Beta7
GTTS-WQ13581MR IVTScrip™ mRNA-Anti-IL13, QAX-576(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA QAX-576
GTTS-WQ5733MR IVTScrip™ mRNA-Anti-CEACAM5, CEA-IL-2v(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA CEA-IL-2v
GTTS-WQ7993MR IVTScrip™ mRNA-Anti-GHR, GX-H9(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA GX-H9
GTTS-WQ816MR IVTScrip™ mRNA-Anti-LRRC15, ABBV-085(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA ABBV-085
GTTS-WQ10707MR IVTScrip™ mRNA-Anti-ALB&IL17A, M-1095(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA M-1095
GTTS-WQ1703MR IVTScrip™ mRNA-Anti-Dabigatran, aDabi-Fab(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA aDabi-Fab
GTTS-WQ5691MR IVTScrip™ mRNA-Anti-GPNMB, CDX-011 (DOX)(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA CDX-011 (DOX)
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW